HRP20200482T1 - Dijagnostičke analize i setovi za detekciju folat receptora 1 - Google Patents
Dijagnostičke analize i setovi za detekciju folat receptora 1 Download PDFInfo
- Publication number
- HRP20200482T1 HRP20200482T1 HRP20200482TT HRP20200482T HRP20200482T1 HR P20200482 T1 HRP20200482 T1 HR P20200482T1 HR P20200482T T HRP20200482T T HR P20200482TT HR P20200482 T HRP20200482 T HR P20200482T HR P20200482 T1 HRP20200482 T1 HR P20200482T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- antibody
- binding fragment
- polypeptide
- seq
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title claims 3
- 102000010451 Folate receptor alpha Human genes 0.000 title 1
- 108050001931 Folate receptor alpha Proteins 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102100035139 Folate receptor alpha Human genes 0.000 claims 8
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 238000004458 analytical method Methods 0.000 claims 3
- 238000004163 cytometry Methods 0.000 claims 3
- 238000003018 immunoassay Methods 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002991 immunohistochemical analysis Methods 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000010185 immunofluorescence analysis Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Claims (13)
1. Antitijelo ili antigen-vezujući fragment istog koje se specifično veže za FOLR1, pri čemu spomenuto antitijelo ili antigen-vezujući fragment istog sadrži VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 i VL-CDR3 sekvence amino kiselina iz: SEQ ID NOs: 1, 2, i 3 te SEQ ID NOs: 13, 14 i 15.
2. Antitijelo ili antigen-vezujući fragment istog prema zahtjevu 1, pri čemu spomenuto antitijelo ili antigen-vezujući fragment istog sadrži sekvence amino kiselina iz: SEQ ID NO: 25 i SEQ ID NO: 29.
3. Antitijelo ili antigen-vezujući fragment istog prema zahtjevu 1 ili 2, pri čemu spomenuto antitijelo ili antigen-vezujući fragment istog je murin, ne-humani, humanizirani, kimerni ili obnovljene površine.
4. Polipeptid koji specifično veže FOLR1, pri čemu spomenuti polipeptid sadrži sekvence iz: SEQ ID NOs: 1, 2, i 3 te SEQ ID NOs: 13, 14 i 15.
5. Molekula nukleinske kiseline koja šifrira antitijelo, antigen-vezujući fragment istog, ili polipeptid prema bilo kojem od zahtjeva 1-4.
6. Postupak detektiranja FOLR1 proteina u uzorku koji sadrži kontaktiranje spomenutog uzorka s antitijelom, antigen-vezujućim fragmentom istog, ili polipeptidom prema bilo kojem od zahtjeva 1-4.
7. Postupak prema zahtjevu 6, pri čemu je FOLR1 protein detektiran radioimunološkom analizom, Western blot analizom, imunofluorescencijskom analizom, enzimskom analizom, imunoprecipitacijskom analizom, kemiluminescencijskom analizom, citometrijom ili imunohistokemijskom analizom.
8. Postupak prema zahtjevu 7, pri čemu se FOLR1 protein detektira citometrijom, enzimskom imunoanalizom, ili imunohistokemijskom analizom, pri čemu citometrija je protočna citometrija, te pri čemu enzimska imunoanaliza je imunosorbentska analiza vezanih enzima (ELISA).
9. Postupak prema zahtjevu 6 ili 7, pri čemu spomenuti FOLR1 protein je ogoljeni FOLR1 protein.
10. Izolirana stanica koja proizvodi antitijelo, antigen-vezujući fragment istog, ili polipeptid prema bilo kojem od zahtjeva 1-4.
11. Postupak proizvodnje antitijela, antigen-vezujućeg fragmenta istog, ili polipeptida prema bilo kojem od zahtjeva 1-4, koji sadrži (a) kultiviranje stanice prema zahtjevu 10; i (b) izoliranje spomenutog antitijela, antigen-vezujućeg fragmenta istog, ili polipeptida iz spomenute kultivirane stanice.
12. Set za imunološku analizu za detekciju FOLR1 proteina u uzorku, set sadrži: (a) prvi reagens, pri čemu prvi reagens je antitijelo ili antigen-vezujući fragment istog prema bilo kojem od zahtjeva 1-3 ili polipeptid prema zahtjevu 4, te (b) drugi reagens, pri čemu drugi reagens je detekcijski reagens.
13. Antitijelo ili antigen-vezujući fragment istog prema bilo kojem od zahtjeva 1 do 3 ili polipeptid prema zahtjevu 4 za uporabu u postupku dijagnosticiranja raka.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261695791P | 2012-08-31 | 2012-08-31 | |
US201361756254P | 2013-01-24 | 2013-01-24 | |
PCT/US2013/057682 WO2014036495A2 (en) | 2012-08-31 | 2013-08-30 | Diagnostic assays and kits for detection of folate receptor 1 |
EP13833526.0A EP2890717B1 (en) | 2012-08-31 | 2013-08-30 | Diagnostic assays and kits for detection of folate receptor 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200482T1 true HRP20200482T1 (hr) | 2020-06-26 |
Family
ID=50184673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200482TT HRP20200482T1 (hr) | 2012-08-31 | 2020-03-24 | Dijagnostičke analize i setovi za detekciju folat receptora 1 |
Country Status (27)
Country | Link |
---|---|
US (6) | US9200073B2 (hr) |
EP (2) | EP2890717B1 (hr) |
JP (6) | JP6293147B2 (hr) |
KR (4) | KR20150046316A (hr) |
CN (2) | CN110294805B (hr) |
AU (4) | AU2013308497B2 (hr) |
BR (1) | BR112015004229B1 (hr) |
CA (2) | CA3137438A1 (hr) |
CY (1) | CY1122907T1 (hr) |
DK (1) | DK2890717T3 (hr) |
ES (1) | ES2788151T3 (hr) |
HK (1) | HK1210188A1 (hr) |
HR (1) | HRP20200482T1 (hr) |
HU (1) | HUE049693T2 (hr) |
IL (4) | IL299620A (hr) |
LT (1) | LT2890717T (hr) |
ME (1) | ME03799B (hr) |
MX (1) | MX362514B (hr) |
NZ (2) | NZ726258A (hr) |
PL (1) | PL2890717T3 (hr) |
PT (1) | PT2890717T (hr) |
RS (1) | RS60217B1 (hr) |
RU (1) | RU2668824C2 (hr) |
SG (2) | SG11201500938XA (hr) |
SI (1) | SI2890717T1 (hr) |
WO (1) | WO2014036495A2 (hr) |
ZA (1) | ZA201707245B (hr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101637138B1 (ko) | 2010-02-24 | 2016-07-06 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
RU2668824C2 (ru) | 2012-08-31 | 2018-10-02 | Иммьюноджен Инк. | Диагностические анализы и наборы для детекции фолатного рецептора 1 |
US20160311921A1 (en) * | 2013-06-20 | 2016-10-27 | Morphotek ,Inc. | Methods for treatment of ovarian cancer |
MX371496B (es) | 2013-08-30 | 2020-01-31 | Immunogen Inc | Anticuerpos y ensayos para la detección del receptor 1 de folato. |
DK3055332T3 (da) * | 2013-10-08 | 2019-12-09 | Immunogen Inc | Anti-folr1-immunkonjugat-doseringsregimer |
WO2015149018A1 (en) * | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
WO2015186823A1 (ja) * | 2014-06-06 | 2015-12-10 | 協和発酵キリン株式会社 | Folr1標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬 |
KR102648966B1 (ko) * | 2014-11-20 | 2024-03-19 | 에프. 호프만-라 로슈 아게 | Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자 |
CA2994888A1 (en) * | 2015-09-17 | 2017-03-23 | Immunogen, Inc. | Therapeutic combinations comprising anti-folr1 immunoconjugates |
CN105548059B (zh) * | 2016-01-29 | 2018-08-24 | 福建医科大学 | 叶酸-牛血清白蛋白-铂铋纳米复合材料 |
WO2017192863A1 (en) * | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
JP7072571B2 (ja) * | 2016-11-23 | 2022-05-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗葉酸受容体アルファ抗体およびその使用 |
CN108982430B (zh) * | 2017-05-31 | 2020-09-29 | 北京大学 | 标记细菌菌群样品的试剂盒、方法及应用 |
CN111108385A (zh) * | 2017-09-05 | 2020-05-05 | 伊缪诺金公司 | 用于检测患者样品中的叶酸受体1的方法 |
KR20200132900A (ko) * | 2018-03-13 | 2020-11-25 | 페인스 테라퓨틱스 인코포레이티드 | 항-폴레이트 수용체 1 항체 및 이의 용도 |
EP3953392A1 (en) * | 2019-04-12 | 2022-02-16 | Phanes Therapeutics, Inc. | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof |
MA55818A (fr) | 2019-04-29 | 2022-03-16 | Immunogen Inc | Anticorps et immunoconjugués de fr-alpha biparatopique |
CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
CN114163520B (zh) * | 2021-11-23 | 2024-01-30 | 南京京达生物技术有限公司 | 一种血源性人IgM抗体纯化介质制备方法 |
CN117700556B (zh) * | 2024-02-05 | 2024-04-12 | 苏州百道医疗科技有限公司 | 一种抗FRα小鼠单克隆抗体及其应用 |
CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1319315A (en) | 1969-06-19 | 1973-06-06 | Citizen Watch Co Ltd | Calendar timepiece |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
EP1186660A3 (fr) | 1985-03-30 | 2002-03-20 | KAUFFMAN, Stuart A. | Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
GB8826530D0 (en) | 1988-11-12 | 1988-12-14 | Ped Capacitors Ltd | Electrical capacitors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3306063B2 (ja) | 1990-08-24 | 2002-07-24 | イグジス, インコーポレイテッド | ランダムコドンを有するオリゴヌクレオチドを合成する方法 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP3298879B2 (ja) | 1990-12-20 | 2002-07-08 | イグジス,インコーポレイテッド | 結合タンパク質の最適化 |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質/(ポリ)ペプチドライブラリー |
US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DK0942968T3 (da) | 1996-12-03 | 2008-06-23 | Amgen Fremont Inc | Fuldt humane antistoffer, der binder EGFR |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
WO2000023082A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
CA2339889C (en) | 1999-07-02 | 2012-01-31 | Morphosys Ag | Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
IT1307309B1 (it) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono. |
IL151927A0 (en) | 2000-03-31 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
DE10037759A1 (de) | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
ES2309167T3 (es) | 2001-02-19 | 2008-12-16 | Merck Patent Gmbh | Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida. |
AU2002258518A1 (en) | 2001-03-14 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
CN101979095A (zh) | 2001-05-02 | 2011-02-23 | 普渡研究基金会 | 巨噬细胞介导的疾病的治疗和诊断 |
US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
AU2003211337A1 (en) | 2002-03-01 | 2003-09-16 | Japan Envirochemicals, Ltd. | Proteins capable of binding to female sex hormones and process for producing the same |
AU2003224073C1 (en) | 2002-04-22 | 2010-03-11 | AgroProtect GmbH | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2004043989A2 (en) | 2002-11-07 | 2004-05-27 | Medarex, Inc. | Human monoclonal antibodies to heparanase |
ZA200503075B (en) | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
JP5416338B2 (ja) | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Cd20特異的抗体およびその使用方法 |
CA2525553C (en) | 2003-05-14 | 2011-07-05 | Immunogen, Inc. | Maytansinoid-antibody conjugate compositions |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
JP2008500949A (ja) | 2003-07-02 | 2008-01-17 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
WO2005054469A1 (en) | 2003-12-05 | 2005-06-16 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
WO2005080431A2 (en) * | 2004-02-12 | 2005-09-01 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
EP1747462A2 (en) | 2004-04-27 | 2007-01-31 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
CA2584859C (en) | 2004-10-25 | 2017-11-07 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
EP2562259B1 (en) | 2004-12-21 | 2016-07-06 | Monsanto Technology LLC | Transgenic plants with enhanced agronomic traits |
BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
EP2153848A3 (en) | 2005-01-27 | 2010-07-21 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins |
PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
WO2006105141A1 (en) | 2005-03-30 | 2006-10-05 | Purdue Research Foundation | Method for cancer prognosis using cellular folate vitamin receptor quantification |
CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
US7786266B2 (en) | 2005-05-12 | 2010-08-31 | Oncotherapy Science, Inc. | Methods for damaging cells using effector function of anti-DSC2 antibody |
ES2864039T3 (es) | 2005-05-20 | 2021-10-13 | Lonza Biologics Plc | Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero |
BRPI0610203A2 (pt) | 2005-05-24 | 2010-06-01 | Avestha Gengraine Tech Pvt Ltd | processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica |
EP1904183B1 (en) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmaceutical composition for the treatment of osteoarthritis |
US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
EP1937720B1 (en) | 2005-08-18 | 2014-04-09 | Ramot at Tel-Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
DK1937815T3 (en) | 2005-09-13 | 2015-08-03 | Nat Res Council Canada | Methods and compositions for the modulation of tumor cell activity |
CA2625403A1 (en) | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
SI2532681T1 (sl) | 2005-12-20 | 2015-03-31 | Sbi Biotech Co., Ltd. | Protitelo proti-ILT7 |
US8486412B2 (en) | 2006-06-01 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
AU2007262635B2 (en) | 2006-06-23 | 2014-09-11 | Adc Therapeutics Sa | Polynucleotides and polypeptide sequences involved in cancer |
US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
US20090182955A1 (en) | 2006-09-08 | 2009-07-16 | Rao Cherukuri | Application configuration across client devices of a local system |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
NZ601022A (en) | 2006-10-12 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody |
AU2007332473B2 (en) | 2006-12-14 | 2012-09-27 | Forerunner Pharma Research Co., Ltd. | Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
EP2121756A4 (en) | 2006-12-20 | 2011-08-31 | Mmrglobal Inc | ANTIBODIES AND PROCESS FOR THEIR PREPARATION AND USE |
US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
EP2609934A1 (en) | 2007-02-16 | 2013-07-03 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
CN101139613B (zh) | 2007-08-01 | 2011-06-08 | 姜荣锡 | 抗肿瘤二元多肽及其应用与制备方法 |
KR101706390B1 (ko) | 2007-12-21 | 2017-02-13 | 노파르티스 아게 | 유기 화합물 |
EP2241578B1 (en) | 2008-01-11 | 2016-04-20 | The University of Tokyo | Anti-cldn6 antibody |
EP2275431A3 (en) | 2008-01-18 | 2011-05-25 | Bio-Rad Laboratories, Inc. | Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
MX2010011621A (es) | 2008-04-21 | 2011-01-14 | Swapsol Corp | Conversion de sulfuro de hidrogeno a hidrogeno. |
WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
JP2011523628A (ja) | 2008-04-30 | 2011-08-18 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
PL2281006T3 (pl) | 2008-04-30 | 2018-01-31 | Immunogen Inc | Środki łączące i ich zastosowania |
US8383351B2 (en) | 2008-06-11 | 2013-02-26 | Oxford Brookes University | Antibody to inhibin/ activin β-B subunit |
US20100069298A1 (en) * | 2008-09-16 | 2010-03-18 | Robert Penny | Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same |
AU2009293140A1 (en) | 2008-09-17 | 2010-03-25 | Endocyte, Inc. | Folate receptor binding conjugates of antifolates |
US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
CN101440130B (zh) | 2008-11-21 | 2011-07-27 | 中国人民解放军第四军医大学 | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 |
EP2411808B1 (en) | 2009-03-24 | 2015-11-11 | Biocept, Inc. | Devices and methods of cell capture and analysis |
US8858949B2 (en) | 2009-08-06 | 2014-10-14 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
AR080155A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos anti-cd20 y su utilizacion |
KR101637138B1 (ko) | 2010-02-24 | 2016-07-06 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
EP2629798A4 (en) * | 2010-10-20 | 2014-05-28 | Morphotek Inc | GLYCOFORMS OF ANTI-RECEPTOR ANTIBODY-ALPHA FOLATE (ANTI-FRA) |
KR101931936B1 (ko) * | 2010-11-05 | 2018-12-26 | 에이자이 아이엔씨. | 엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파 |
SI2691155T1 (sl) | 2011-03-29 | 2019-03-29 | Immunogen, Inc. | Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom |
BR112013025228A2 (pt) | 2011-03-29 | 2018-09-25 | Immunogen Inc | processo para fabricar conjugados de homogeneidade aperfeçoada |
BR112013025415B1 (pt) | 2011-04-01 | 2021-03-16 | Immunogen, Inc | uso de um imunoconjugado antirreceptor de folato 1 (folr1) |
US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
TR201802838T4 (tr) | 2011-07-15 | 2018-03-21 | Eisai R&D Man Co Ltd | Anti-folat reseptör alfa antikorlar ve bunların kullanımı. |
RU2668824C2 (ru) | 2012-08-31 | 2018-10-02 | Иммьюноджен Инк. | Диагностические анализы и наборы для детекции фолатного рецептора 1 |
KR20150094617A (ko) | 2012-12-07 | 2015-08-19 | 교와 핫꼬 기린 가부시키가이샤 | 항 folr1 항체 |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
SG11201509043RA (en) | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
MX371496B (es) | 2013-08-30 | 2020-01-31 | Immunogen Inc | Anticuerpos y ensayos para la detección del receptor 1 de folato. |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
DK3055332T3 (da) | 2013-10-08 | 2019-12-09 | Immunogen Inc | Anti-folr1-immunkonjugat-doseringsregimer |
WO2015149018A1 (en) | 2014-03-28 | 2015-10-01 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
CA2994888A1 (en) | 2015-09-17 | 2017-03-23 | Immunogen, Inc. | Therapeutic combinations comprising anti-folr1 immunoconjugates |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2013
- 2013-08-30 RU RU2015104579A patent/RU2668824C2/ru active
- 2013-08-30 PL PL13833526T patent/PL2890717T3/pl unknown
- 2013-08-30 WO PCT/US2013/057682 patent/WO2014036495A2/en active Application Filing
- 2013-08-30 US US14/015,653 patent/US9200073B2/en active Active
- 2013-08-30 SG SG11201500938XA patent/SG11201500938XA/en unknown
- 2013-08-30 KR KR1020157007933A patent/KR20150046316A/ko not_active Application Discontinuation
- 2013-08-30 HU HUE13833526A patent/HUE049693T2/hu unknown
- 2013-08-30 IL IL299620A patent/IL299620A/en unknown
- 2013-08-30 JP JP2015530124A patent/JP6293147B2/ja active Active
- 2013-08-30 DK DK13833526.0T patent/DK2890717T3/da active
- 2013-08-30 CA CA3137438A patent/CA3137438A1/en active Pending
- 2013-08-30 EP EP13833526.0A patent/EP2890717B1/en active Active
- 2013-08-30 KR KR1020207018333A patent/KR20200079565A/ko not_active Application Discontinuation
- 2013-08-30 NZ NZ726258A patent/NZ726258A/en unknown
- 2013-08-30 SI SI201331702T patent/SI2890717T1/sl unknown
- 2013-08-30 MX MX2015002605A patent/MX362514B/es active IP Right Grant
- 2013-08-30 SG SG10201804260QA patent/SG10201804260QA/en unknown
- 2013-08-30 ES ES13833526T patent/ES2788151T3/es active Active
- 2013-08-30 CA CA2883222A patent/CA2883222C/en active Active
- 2013-08-30 RS RS20200501A patent/RS60217B1/sr unknown
- 2013-08-30 KR KR1020237043959A patent/KR20240005129A/ko active Search and Examination
- 2013-08-30 BR BR112015004229-5A patent/BR112015004229B1/pt active IP Right Grant
- 2013-08-30 EP EP20160627.4A patent/EP3712175A1/en active Pending
- 2013-08-30 CN CN201910418596.XA patent/CN110294805B/zh active Active
- 2013-08-30 LT LTEP13833526.0T patent/LT2890717T/lt unknown
- 2013-08-30 CN CN201380045151.2A patent/CN104755498B/zh active Active
- 2013-08-30 ME MEP-2020-142A patent/ME03799B/me unknown
- 2013-08-30 AU AU2013308497A patent/AU2013308497B2/en active Active
- 2013-08-30 KR KR1020217038453A patent/KR102617499B1/ko active IP Right Grant
- 2013-08-30 PT PT138335260T patent/PT2890717T/pt unknown
- 2013-08-30 NZ NZ630433A patent/NZ630433A/en unknown
-
2015
- 2015-02-04 IL IL237087A patent/IL237087B/en active IP Right Grant
- 2015-10-23 US US14/921,596 patent/US9702881B2/en active Active
- 2015-11-03 HK HK15110850.1A patent/HK1210188A1/xx unknown
-
2017
- 2017-06-12 US US15/620,117 patent/US10180432B2/en active Active
- 2017-10-25 ZA ZA2017/07245A patent/ZA201707245B/en unknown
- 2017-12-25 JP JP2017247587A patent/JP6480558B2/ja active Active
-
2018
- 2018-03-20 JP JP2018052302A patent/JP2018088942A/ja not_active Withdrawn
- 2018-06-04 AU AU2018203934A patent/AU2018203934B2/en active Active
- 2018-11-28 US US16/203,276 patent/US10613093B2/en active Active
-
2019
- 2019-02-11 IL IL264770A patent/IL264770B/en active IP Right Grant
- 2019-11-11 JP JP2019203933A patent/JP2020018325A/ja active Pending
-
2020
- 2020-02-28 US US16/804,664 patent/US20200333347A1/en not_active Abandoned
- 2020-03-24 HR HRP20200482TT patent/HRP20200482T1/hr unknown
- 2020-04-30 CY CY20201100401T patent/CY1122907T1/el unknown
- 2020-07-09 AU AU2020204602A patent/AU2020204602B2/en active Active
-
2021
- 2021-02-03 IL IL280634A patent/IL280634B2/en unknown
- 2021-12-10 JP JP2021200640A patent/JP7289346B2/ja active Active
-
2022
- 2022-06-02 US US17/831,254 patent/US20230213524A1/en active Pending
-
2023
- 2023-05-30 JP JP2023088416A patent/JP2023111942A/ja active Pending
- 2023-08-04 AU AU2023210668A patent/AU2023210668A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200482T1 (hr) | Dijagnostičke analize i setovi za detekciju folat receptora 1 | |
JP7022969B2 (ja) | SARS-CoV-2感染症を診断するための方法および試薬 | |
JP2018042573A5 (hr) | ||
HRP20211317T1 (hr) | Antitijela i analize za detekciju folat receptora 1 | |
DK2564202T3 (en) | A method for detecting anti-drug antibodies | |
MX2014001377A (es) | Metodo para detectar cancer pancreatico. | |
HRP20211889T1 (hr) | Antitijela sa jednom domenom usmjerena protiv intracelularnih antigena | |
Tateno et al. | A medium hyperglycosylated podocalyxin enables noninvasive and quantitative detection of tumorigenic human pluripotent stem cells | |
JP2015533788A5 (hr) | ||
RU2013125772A (ru) | Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецепторов фолиевой кислоты альфа | |
CA2886779C (en) | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction | |
RU2009141523A (ru) | Биомаркеры для рассеянного склероза | |
RU2013142334A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а | |
US10132806B2 (en) | Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis | |
WO2011074594A1 (ja) | 悪性腫瘍の診断方法 | |
RU2019113127A (ru) | REP белок в качестве белкового антигена для диагностических анализов | |
EA201400571A1 (ru) | Специфичные к трансресвератролу антитела и их применение | |
Kusano-Arai et al. | Kinetic exclusion assay of monoclonal antibody affinity to the membrane protein Roundabout 1 displayed on baculovirus | |
KR102426782B1 (ko) | SARS-CoV-2 RBD 항원 특이적 항체를 포함하는 진단용 조성물 또는 키트 | |
US9784751B2 (en) | Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain | |
US9528994B2 (en) | Target of the phosphoinositide 3-kinase pathway | |
US10401371B2 (en) | Method of measuring cholesterol levels by using immunogenic method | |
Chourb et al. | Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay | |
WO2014083040A2 (en) | Progranulin as marker for autoimmune disorders | |
US11267854B2 (en) | Complex-specific standardization of immunological methods for the quantification of S100A12 |